Aura Biosciences Reports $33.7 Million Net Loss in Q1 2026, Increases R&D Spending

Aura Biosciences, Inc. reported a net loss of $33.7 million for the first quarter of 2026, an increase from a net loss of $27.5 million during the same period in 2025. The company's total operating expenses rose to $34.9 million, compared to $29.0 million in the prior year, primarily driven by increased research and development costs associated with its lead candidate, bel-sar, which is in late-stage clinical trials for treating choroidal melanoma. Research and development expenses alone increased to $28.0 million from $23.3 million, reflecting ongoing clinical trial costs and manufacturing development.

In terms of financial position, Aura's cash and cash equivalents, along with marketable securities, totaled $114.7 million as of March 31, 2026, a decrease from $149.7 million at the end of 2025. The company completed a significant financing event in May 2026, raising approximately $280.8 million in net proceeds from a follow-on offering, which included the sale of 46.1 million shares of common stock. This capital infusion is expected to support operations into the second half of 2028, alleviating previous concerns about liquidity.

Operationally, Aura has made strides in its clinical development pipeline, particularly with bel-sar, which has shown promising results in early trials. The company is also expanding its focus to include additional indications such as bladder cancer and ocular surface cancers. As of March 31, 2026, the company had 64.2 million shares outstanding, reflecting a modest increase from 63.6 million shares at the end of 2025, indicating ongoing equity financing activities.

The company’s strategic initiatives include the repurchase of shares from Matrix Capital Management, which amounted to approximately $39.0 million, executed shortly after the follow-on offering. This move is part of Aura's broader strategy to manage its capital structure effectively. Looking ahead, Aura anticipates continued increases in operating expenses as it advances its clinical trials and expands its research capabilities, necessitating further capital raises to sustain its growth trajectory.

Overall, while Aura Biosciences continues to face significant operating losses, the recent capital raise and ongoing clinical developments position the company to potentially address unmet medical needs in oncology, particularly in ocular and urologic cancers. The management remains focused on executing its clinical trials and exploring additional funding avenues to support its long-term objectives.